GSK submits diabetes drug albiglutide to FDA review

01/14/2013 | Reuters

GlaxoSmithKline has applied to the FDA for approval to market albiglutide, an experimental weekly drug for diabetes. Albiglutide belongs to a class of drugs called GLP-1 agonists that includes Novo Nordisk's Victoza. GSK plans to submit the drug for approval in Europe as well.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC